Thyroid Cancer Drugs Industry and Companies Analysis Report 2025: A $2.2 Billion Landscape by 2029 [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Key players include Eli Lilly, Bristol Myers Squibb, and AstraZeneca. As North America leads, the Middle East is predicted to see the fastest growth. Dublin, April 16, 2025 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Market Report 2025" has been added to ResearchAndMarkets.com's offering. The thyroid cancer drugs market has demonstrated significant growth and is projected to continue its expansion from $1.17 billion in 2024 to $1.35 billion in 2025, registering a CAGR of 15.5%. Further growth is anticipated, with the market estimated to reach $2.2 billion by 2029 at a CAGR of 13%. This growth is fueled by the rising incidence of thyroid cancer, particularly among women, advancements in medical research, and increasing healthcare expenditure globally. In 2022, the American Cancer Society reported 43,800 estimated new cases of thyroid cancer in the United States, with women holding a significant majority. Rising healthcare spending is a key driver of market growth, as evidenced
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026Business Wire
- Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Canada Welcomes Positive CDA Recommendation for OPDIVO® Plus YERVOY® as First-Line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Advancium Health Network Names Michele Cleary CEO to Drive Next Phase of Pediatric Healthcare Innovation [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 11/18/25 - Form 8-K
- 11/12/25 - Form CERT
- 11/10/25 - Form 8-A12B
- BMY's page on the SEC website